These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

61 related items for PubMed ID: 1470565

  • 1. The influence of C-terminal cholecystokinin fragments in the circulatory system of rats.
    Wiśniewska RJ, Kupryszewski G.
    Pol J Pharmacol Pharm; 1992; 44(3):281-7. PubMed ID: 1470565
    [Abstract] [Full Text] [Related]

  • 2. Effects of cholecystokinin (CCK-33) and its fragments, C-terminal octapeptide (CCK-8) and C-terminal tetrapeptide (CCK-4), on the circulatory system of diabetic rats.
    Fiedorowicz RJ, Wiśniewski K.
    Pol J Pharmacol Pharm; 1989; 41(6):561-72. PubMed ID: 2485904
    [Abstract] [Full Text] [Related]

  • 3. Interaction of cholecystokinin (CCK-8) with agonist and antagonist of beta-adrenergic receptors in circulatory system of diabetic rats.
    Wiśniewska RJ, Wiśniewski K.
    Pol J Pharmacol; 1996; 48(3):293-7. PubMed ID: 9112665
    [Abstract] [Full Text] [Related]

  • 4. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of rats. Part A.
    Wiśniewska RJ.
    Pol J Pharmacol; 1998; 50(3):203-12. PubMed ID: 9861628
    [Abstract] [Full Text] [Related]

  • 5. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of diabetic rats. Part B.
    Wiśniewska RJ.
    Pol J Pharmacol; 1998; 50(3):213-23. PubMed ID: 9861629
    [Abstract] [Full Text] [Related]

  • 6. The interaction of cholecystokinin and its fragments with norepinephrine in the circulatory system of diabetic rats.
    Fiedorowicz RJ, Wiśniewski K.
    Pol J Pharmacol Pharm; 1989; 41(6):573-83. PubMed ID: 2577226
    [Abstract] [Full Text] [Related]

  • 7. The effect of pentagastrin, cholecystokinin and their analogues on rat arterial blood pressure and isolated heart.
    Wiśniewska R, Wiśniewski K.
    Rocz Akad Med Bialymst; 1996; 41(2):183-90. PubMed ID: 9020529
    [Abstract] [Full Text] [Related]

  • 8. The effect of cholecystokinin (CCK-33) and C-terminal fragments of cholecystokinin: CCK-8 and CCK-4 on the cardiovascular system in rats.
    Wiśniewska RJ, Wiśniewski K.
    Gen Pharmacol; 1996 Jan; 27(1):159-63. PubMed ID: 8742514
    [Abstract] [Full Text] [Related]

  • 9. Effects of cholecystokinin-related peptides on retention of passive avoidance behaviour.
    Fekete M, Penke B, Telegdy G.
    Acta Physiol Acad Sci Hung; 1982 Jan; 60(4):237-42. PubMed ID: 6314742
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the behavioral activity of C- and N-terminal fragments of cholecystokinin octapeptide.
    Crawley JN, St-Pierre S, Gaudreau P.
    J Pharmacol Exp Ther; 1984 Aug; 230(2):438-44. PubMed ID: 6086888
    [Abstract] [Full Text] [Related]

  • 11. Effects of cholecystokinin octapeptide on rat cardiac function and the receptor mechanism.
    Zhao XY, Ling YL, Meng AH, Shan BE, Zhang JL.
    Sheng Li Xue Bao; 2002 Jun 25; 54(3):239-43. PubMed ID: 12075472
    [Abstract] [Full Text] [Related]

  • 12. Activation of central nervous system cholecystokinin receptors stimulates respiration in the cat.
    Gillis RA, Quest JA, Pagani FD, Souza JD, Da Silva AM, Jensen RT, Garvey TQ, Hamosh P.
    J Pharmacol Exp Ther; 1983 Feb 25; 224(2):408-14. PubMed ID: 6296361
    [Abstract] [Full Text] [Related]

  • 13. [Cholecystokinin-octapeptide antagonizes the central depressive effect of opioid peptides in rats].
    Mei L, Han JS.
    Sheng Li Xue Bao; 1991 Apr 25; 43(2):156-63. PubMed ID: 2068585
    [Abstract] [Full Text] [Related]

  • 14. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
    Povoski SP, Zhou W, Longnecker DS, Roebuck BD, Bell RH.
    Cancer Res; 1993 Sep 01; 53(17):3925-9. PubMed ID: 8358719
    [Abstract] [Full Text] [Related]

  • 15. Effects of intraventricular administration of cholecystokinin octapeptide sulfate ester and unsulfated cholecystokinin octapeptide on active avoidance and conditioned feeding behaviour of rats.
    Fekete M, Szabó A, Balázs M, Penke B, Telegdy G.
    Acta Physiol Acad Sci Hung; 1981 Sep 01; 58(1):39-45. PubMed ID: 6282048
    [Abstract] [Full Text] [Related]

  • 16. Effects of cholecystokinin, caerulein and pentagastrin on arterial blood pressure and plasma renin activity in rats.
    Wiśniewska RJ.
    Pol J Pharmacol; 1997 Sep 01; 49(6):419-23. PubMed ID: 9566045
    [Abstract] [Full Text] [Related]

  • 17. [The immunostimulating properties of cholecystokinin octapeptide and its fragments].
    Molchanova IV, Belokrylov GA, Popova OIa, Kalikhevich VN.
    Biull Eksp Biol Med; 1992 Dec 01; 114(12):631-3. PubMed ID: 1292696
    [Abstract] [Full Text] [Related]

  • 18. Cholecystokinin (CCK) and C-terminal fragments of CCK: effects of CCK-33, CCK-8 and CCK-4 in the cardiovascular system of diabetic rats.
    Wiśniewska RJ, Wiśniewski K.
    Gen Pharmacol; 1996 Mar 01; 27(2):399-405. PubMed ID: 8919664
    [Abstract] [Full Text] [Related]

  • 19. [Cholecystokinin octapeptide antagonized the effect of NDAP on CaM in rat dorsal spinal synaptosome].
    Chen SZ, Han JS.
    Sheng Li Xue Bao; 1994 Apr 01; 46(2):120-5. PubMed ID: 7973792
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
    Fossa AA, DePasquale MJ, Morrone J, Zorn SH, Bryce D, Lowe JA, McLean S.
    J Pharmacol Exp Ther; 1997 Apr 01; 281(1):180-7. PubMed ID: 9103496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.